Home›Trial›NCT03821935
🔬NCT03821935Phase 1ACTIVE NOT RECRUITING

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Study Summary

The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.

Conditions
Advanced Solid Tumors Cancer
Interventions / Drugs
LivmoniplimabBudigalimab
View on ClinicalTrials.gov ↗
Sponsor
ABBV
AbbVie Inc
Immunology
C64/100
Study Details
Enrollment364 participants
Primary Completion—
Lead SponsorAbbVie
Data Retrieved2026-04-11 02:51:51.324921+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.